. Although the probability to find an unrelated donor has recently reached almost 80% for white Europeans, it still remains around 41% only for Chinese patients (2) . Further, while waiting for a volunteer donor, the risk of early relapse remains, highlighting the need for alternative sources of donors.
Initially, haploidentical donor transplantation has been pioneered by the Perugia team (3), using T depleted CD34+ selected megadose stem cells and highly myeloablative pretransplant regimens. Recently, in the US and then in Europe, a considerable improvement has occurred with the shift to T replete grafts and the introduction of High dose cyclophosphamide post graft infusion for the prevention of graft versus host disease (GVH) (4) . In China, the "Beijing group" has pioneered a different approach with T replete HID, intensive myeloablation, combination of G-CSF primed bone marrow plus Peripheral blood as stem cell source and anti-thymocyte globulins (ATG) (5) . This team has reported a large series of haploidentical transplants for AML in CR1, with Leukemia free survival (LFS) as high as 70% and a very low incidence of both acute and Chronic GVHD. Interval from CR1 to transplant less than or greater than 6 months, and (3) Numbers of induction courses to reach CR1 of one or more than one. The primary endpoint was LFS, and the secondary endpoints were overall survival (OS), relapse incidence (RI), non-relapse mortality (NRM).
We were able to match 87 HID with 87 URD patients. The two matched groups were comparable in donor and patient sex, year of transplant, number of induction courses to reach CR1, and time interval from diagnosis to transplant. We however have to admit that this preliminary study has several limitations: A first one is related to the fact that this study is a comparison between a single center and a registry. A second one is that we have no details on the induction regimens used in China to achieve (one or more than one) and the interval from CR1 to transplant as a surrogate marker for the numbers of consolidation courses before transplant ( less than or greater than 6 months).
A third limitation is related to the low statistical power which resulted from the small patient population involved.
A fourth limitation of this study is the lack of molecular information (such as FLT3-ITD and NPM1) for the Chinese patients which precluded matching also for this important prognostic factor. We therefore cannot be sure that the two populations were comparable regarding molecular markers. Indeed there has been two recent series of Chinese patients with AML evaluated for molecular biology markers: in a first cohort of 1185 patients analyzed in 2011 (12) as well as in a second cohort of 269 Chinese patients analyzed in 2015 (13), there was a lower frequency than in other European and US series of several markers such as DNMT3A , NRAS , NF1 and TP53 . The frequency of the FLT3ITD mutation however varied from 10% in the first study to 23% in the second one, similar to the 25% reported from the UK MRC AML10 and 12 trials.
Finally, it also has been recently shown that susceptibility to severe acute GVHD is lower in Asian patients than in Caucasian patients (14) , which may account for more successful outcome in Beijing. Despites these limitations, our study as well as others indeed suggest that HID may replace URD at least in some countries such as in China.
The good outcome observed in Beijing reflects in fact a whole transplant strategy which combines a unique conditioning regimen of 4 drugs (cytarabine, busulfan, cyclophosphamide and methyl-CCNU) without TBI, the combination of G-CSF mobilized blood and marrow cells for grafting, and the use of 4 different immunosuppressive medications (rabbit ATG, cyclosporine, mycophenolate mofetil and methotrexate) for GVH prevention. We cannot of course sort out the contribution of each of these four factors for the successful outcome achieved.
In conclusion, this retrospective study suggests that HID transplantation may be an alternative to allogeneic transplantation using a full matched 10/10 URD transplantation in patients with AML in CR1. 
